UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008935
Receipt number R000010473
Scientific Title The study of the new regimen of the AZT administration to the neonate for preventing HIV mother-to-child transmission
Date of disclosure of the study information 2012/09/17
Last modified on 2023/03/27 14:24:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of the new regimen of the AZT administration to the neonate for preventing HIV mother-to-child transmission

Acronym

Comparative analysis of the effectiveness and safety between two regimens; AZT 2mg/kg four times a day for 6 weeks (previous regimen) and AZT 4mg/kg twice a day for 6 weeks (new regimen)

Scientific Title

The study of the new regimen of the AZT administration to the neonate for preventing HIV mother-to-child transmission

Scientific Title:Acronym

Comparative analysis of the effectiveness and safety between two regimens; AZT 2mg/kg four times a day for 6 weeks (previous regimen) and AZT 4mg/kg twice a day for 6 weeks (new regimen)

Region

Japan


Condition

Condition

HIV

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We examine the effectiveness and safety in the new regimen, AZT 4mg/kg twice a day for 6 weeks, in the neonate who was born from HIV-positive mother.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1)HIV transmission at 1 year and 6 month: HIV antibody detection
2)The degree of born marrow suppression: The minimum number of hemoglobin, white blood cell, neutrophile count, platelet between initial AZT administration and 1 or 2 months after completion.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The neonates are given 4mg/kg of AZT twice a day for 6 weeks orally/intravenously

Extension criteria
The neonates who receive HIV or suspected HIV infection

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 days-old <=

Age-upper limit

30 days-old >

Gender

Male and Female

Key inclusion criteria

1)The neonates who are born by HIV positive mother in National Center for Global Health and Medicine (NCGM)
2)The agreement was obtained from the HIV positive mother after verbal explanation of the purposes of the study.

Key exclusion criteria

The mother rejects the agreement for this study.

Target sample size

12


Research contact person

Name of lead principal investigator

1st name Mizue
Middle name
Last name Tanaka

Organization

National Center for
Global Health and Medicine

Division name

pediatric

Zip code

1628655

Address

1-21-1 Toyama,Shinjuku-ku,Tokyo162-8655 JAPAN

TEL

03-3202-7181

Email

mitanaka@hosp.ncgm.go.jp


Public contact

Name of contact person

1st name Mizue
Middle name
Last name Tanaka

Organization

National Center for Global Health and Medicine

Division name

pediatric

Zip code

1628655

Address

1-21-1 Toyama,Shinjuku-ku,Tokyo162-8655 JAPAN

TEL

03-3202-7181

Homepage URL


Email

mitanaka@hosp.ncgm.go.jp


Sponsor or person

Institute

National Center for Global Health and Medicine

Institute

Department

Personal name



Funding Source

Organization

National Center for Global Health and Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Center for Global Health and Medicine

Address

1-21-1 Toyama,Shinjuku-ku,Tokyo162-8655 JAPAN

Tel

03-3202-7181

Email

rinrijm@hosp.ncgm.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 09 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 09 Month 03 Day

Date of IRB

2012 Year 08 Month 16 Day

Anticipated trial start date

2012 Year 09 Month 03 Day

Last follow-up date

2020 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete

2021 Year 12 Month 31 Day

Date analysis concluded

2022 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2012 Year 09 Month 17 Day

Last modified on

2023 Year 03 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010473


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name